Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Other Events
ITEM 8.01.
Pulse Biosciences, Inc. (NASDAQ:PLSE) Files An 8-K Other Events
On April 6, 2020, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing the filing of a registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company currently expects to receive gross proceeds of approximately $30 million.
The net proceeds of the rights offering will be used for general working capital purposes, including the ongoing investment in current and future clinical studies evaluating the safety and efficacy of the Company’s proprietary Nano-Pulse Stimulation™ technology, the development and enhancement of the Company’s CellFX® System, obtaining regulatory clearance for the CellFX® System, sales and marketing activities, and general corporate operations. The Company may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although the Company has no present commitments or agreements to do so.
The rights offering includes an over-subscription right, which permits each rights holder that exercises the basic subscription right in full the option to purchase additional shares of common stock that remain unsubscribed at the expiration of the offering. The over-subscription right is subject to the availability and allocation of shares among holders exercising their over-subscription right, as further described in the rights offering documents.
A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Pulse Biosciences, Inc. Exhibit
EX-99.1 2 nt10010624x2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Pulse Biosciences files Registration Statement for Rights Offering HAYWARD,…
To view the full exhibit click
EX-99.1 2 nt10010624x2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Pulse Biosciences files Registration Statement for Rights Offering HAYWARD,…
To view the full exhibit click
here
About Pulse Biosciences, Inc. (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
